EGFR and neoplasm: Next-generation sequencing analysis was performed using capture-based targeted sequencing across a panel of 520 genes (Burning Rock Biotech, Guangzhou, China) on tumor tissues and plasma to identify genomic alterations, which identified EGFR exon 21 L858R mutation (mutation allele frequency in tissue: 44.7%), CDK12 amplification (copy number in tissue: 21.4), ERBB2 amplification (copy number in tissue: 24.6) as well as a TMB of 7.89 mutations/Mb, with microsatellite stability (MSS) (Table 1).